Cancer Research UK Manchester Institute
In research, Cancer Research UK Manchester Institute stands highest in Medicine (#4,489 of 10,443 worldwide) and Health Sciences (#5,983 of 11,982 worldwide), 2022–2025. Relative to its size it is most specialised in Oncology — Oncology is 13.0× its share of world research.
- World rank, 2022–2025
- #7,717 of 28,054 · #3,535 all time
- Rank in United Kingdom
- #296 of 1,094
- Research works
- 2.6k ▼ 18% vs 2013–17
- Citations
- 118k 45.0 per fractional work
- Top-10% rate
- 24.9% record average 16.5%
- Open access
- 37% world 28%
What is Cancer Research UK Manchester Institute known for in research?
The fields where it stands highest, 2022–2025, ranked among every institution above the floor in each field.
| Field | World rank | Where that sits | Top-10% rate | Works | All time |
|---|---|---|---|---|---|
| MedicineField | #4,489 of 10,443 | 22.4% | 101 | #2163 | |
| Health SciencesDomain | #5,983 of 11,982 | 22.3% | 103 | #2794 |
Each strip is that field’s whole ranked pool, with the notch where Cancer Research UK Manchester Institute sits in it, in the colour of the band that rank falls in. The track under the rate is the rate itself: it carries no world mark, because the world rate differs by field (from about 6% to 21% in this record).
What does Cancer Research UK Manchester Institute specialise in?
Where its research is concentrated relative to its size: Oncology takes 13.0× the share of its output that it takes of world research.
- OncologySubfield · 23.7 works13×
Location quotient, a volume reading rather than an impact one. It surfaces small, lopsided specialities.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Biochemistry, Genetics and Molecular Biology, 4.2×. Every wedge is a field page.
- Biochemistry, Genetics and Molecular Biology 4.2×
- Immunology and Microbiology 3.6×
- Medicine 3.2×
- Physics and Astronomy 1.1×
- Pharmacology, Toxicology and Pharmaceutics 0.7×
- Mathematics 0.5×
- Health Professions 0.4×
- Economics, Econometrics and Finance 0.4×
- Chemistry 0.3×
- Neuroscience 0.2×
- Veterinary 0.2×
- Computer Science 0.2×
- Dentistry 0.2×
- Nursing 0.1×
- Engineering 0.1×
- Agricultural and Biological Sciences 0.1×
- Environmental Science 0.1×
- Materials Science 0.1×
- Psychology 0.1×
- Decision Sciences 0.1×
- Social Sciences 0.1×
- Business, Management and Accounting 0.0×
Who are the top researchers at Cancer Research UK Manchester Institute?
Ranked on the composite score, M. Ebert, E. J. Land and David J. Scott lead among researchers whose main affiliation is Cancer Research UK Manchester Institute.
- 1 M. Ebert United Kingdom · #76,758 worldwide 513 citations · 25 works
- 2 E. J. Land United Kingdom · #85,163 worldwide 332 citations · 46 works
- 3 David J. Scott United Kingdom · #99,301 worldwide 195 citations · 44 works
- 4 Christopher S. Potten United Kingdom · #113,049 worldwide 180 citations · 37 works
- 5 Peter L. Stern United Kingdom · #131,635 worldwide 166 citations · 38 works
- 6 A. J. BATEMAN United Kingdom · #143,326 worldwide 792 citations · 19 works
- 7 Caroline Dive United Kingdom · #162,178 worldwide 486 citations · 150 works
- 8 Geoffrey P. Margison United Kingdom · #175,186 worldwide 112 citations · 32 works
- 9 T. M. Dexter United Kingdom · #175,949 worldwide 125 citations · 26 works
- 10 Nydia G. Testa United Kingdom · #223,314 worldwide 85 citations · 25 works
Which keywords describe research at Cancer Research UK Manchester Institute?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Chemotherapy, Immunotherapy, Clinical Trials, Targeted Therapy, Prognostic Factors, Tumor Microenvironment, Cancer and Biomarkers.
- Cancer Immunotherapy
- Ovarian Cancer
- Human Papillomavirus
- PD-1 and PD-L1
- Adjuvant Therapy
- ALK Inhibitors
- Treatment Guidelines
- Immunity
- Dosimetry
- Cancer Genomics
- Precision Medicine
- Clinical Practice Guidelines
- Genomic Profiling
- Genomic Instability
- Survival Analysis
- Metastasis
- Biomarkers
- Prognostic Factors
- Targeted Therapy
- Immunotherapy
- Chemotherapy
- Clinical Trials
- Cancer
- Tumor Microenvironment
- Radiotherapy
- Inflammation
- Cancer Therapy
- Genetic Mutations
- Gene Expression
- Neoadjuvant Therapy
- Breast Cancer
- Mutational Signatures
- Prostate Cancer
- Tumor Staging
- Tumor Markers
- EGFR Mutations
- Immune Checkpoint Blockade
- Radiation Therapy
- Monte Carlo Simulation
- PET Imaging
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Chemotherapy17▲ 15×21 topics
- Immunotherapy14▲ 12×15 topics
- Clinical Trials13▲ 12×10 topics
- Targeted Therapy12▲ 34×4 topics
- Cancer11▲ 5.1×36 topics
- Prognostic Factors10▲ 14×13 topics
- Tumor Microenvironment9▲ 13×7 topics
- Biomarkers9▲ 8.0×10 topics
- Radiotherapy8▲ 13×11 topics
- Metastasis8▲ 14×12 topics
- Inflammation7▲ 2.2×38 topics
- Survival Analysis7▲ 16×7 topics
- Cancer Therapy7▲ 7.4×13 topics
- Genomic Instability6▲ 36×3 topics
- Genetic Mutations6▲ 8.9×10 topics
- Genomic Profiling6▲ 37×2 topics
- Gene Expression6▲ 5.6×10 topics
- Clinical Practice Guidelines5▲ 6.0×10 topics
- Neoadjuvant Therapy5▲ 14×5 topics
- Precision Medicine5▲ 6.7×6 topics
- Breast Cancer5▲ 12×11 topics
- Cancer Genomics5▲ 40×1 topic
- Mutational Signatures5▲ 40×1 topic
- Dosimetry4▲ 38×2 topics
- Prostate Cancer4▲ 21×4 topics
- Immunity4▲ 6.1×6 topics
- Tumor Staging4▲ 22×2 topics
- Treatment Guidelines4▲ 11×2 topics
- Tumor Markers4▲ 28×2 topics
- ALK Inhibitors4▲ 36×1 topic
- EGFR Mutations4▲ 36×1 topic
- Adjuvant Therapy3▲ 16×2 topics
- Immune Checkpoint Blockade3▲ 19×1 topic
- PD-1 and PD-L13▲ 19×1 topic
- Radiation Therapy3▲ 16×4 topics
- Human Papillomavirus3▲ 17×3 topics
- Monte Carlo Simulation3▲ 10×2 topics
- Ovarian Cancer3▲ 23×3 topics
- PET Imaging3▲ 12×4 topics
- Cancer Immunotherapy3▲ 13×3 topics
Which research topics does Cancer Research UK Manchester Institute publish most on?
By volume in 2022–2025: Cancer Genomics and Diagnostics, Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers and Advanced Radiotherapy Techniques.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Cancer Genomics and Diagnostics Cancer Research 5 works
- 2 Lung Cancer Treatments and Mutations Pulmonary and Respiratory Medicine 4 works
- 3 Cancer Immunotherapy and Biomarkers Oncology 3 works
- 4 Advanced Radiotherapy Techniques Radiation 3 works
- 5 Acute Myeloid Leukemia Research Hematology 3 works
- 6 Lung Cancer Research Studies Oncology 3 works
- 7 Lung Cancer Diagnosis and Treatment Pulmonary and Respiratory Medicine 3 works
- 8 Prostate Cancer Treatment and Research Pulmonary and Respiratory Medicine 2 works
- 9 Immunotherapy and Immune Responses Immunology 2 works
- 10 Ovarian cancer diagnosis and treatment Reproductive Medicine 2 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Cancer Research UK Manchester Institute's research output changed?
Output in 2018–2022 was 18% lower than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Manchester
- University of Manchester
- Manchester Metropolitan University
- Manchester Royal Infirmary
- Manchester Academic Health Science Centre
- The Christie Hospital
- Manchester University NHS Foundation Trust
- Wythenshawe Hospital
- Royal Manchester Children's Hospital
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.